Cellectar Biosciences, Inc.

Cellectar Biosciences maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 1.9, indicating adequate short-term liquidity coverage. The company holds $8.35 million in cash and equivalents against total liabilities of $6.40 million, resulting in a net cash position that supports near-term operations. However, the firm reports a negative return on equity of -1.69 and a negative return on assets of -0.51, reflecting the pre-revenue nature of its business model. The market capitalization stands at $11.96 million, trading at a price-to-book ratio of 2.53, while enterprise value to EBITDA is negative due to operating losses.

Profitability remains deeply negative, with Q1 2026 net income at -$5.65 million and operating income at -$5.79 million, driven by research and development expenses and general administrative costs. The company generates no revenue, resulting in undefined margin metrics and a reliance on external capital to sustain operations. Free cash flow for the period was -$4.85 million, closely tracking operating cash flow of -$4.85 million, with minimal capital expenditures of $3,378. These figures are consistent with early-stage biotechnology firms that prioritize clinical development over immediate profitability.

The company operates as a single reportable segment, with all activities focused on the research and development of its PDC platform for oncology applications. Geographic exposure is concentrated in the United States, as indicated by the primary jurisdiction of operations and filings. There is no diversification across business lines or international markets, creating a high concentration risk in both product pipeline success and domestic regulatory outcomes.

Growth trajectory is characterized by sustained cash burn rather than revenue expansion, as the company has not yet commercialized any products. The historical pattern shows recurring losses and increasing reliance on equity financing to fund operations, with no positive revenue history to analyze for trend growth. The absence of revenue means traditional growth metrics are inapplicable, and progress is measured by clinical milestones and capital raising activities rather than sales volume.

Risk factors include high liquidity risk due to the pre-revenue status and substantial doubt about the company's ability to continue as a going concern without further capital raises. Dilution risk is assessed as medium, with filings referencing offering risks and the presence of multiple warrant series and convertible preferred stock that could increase share count. The company has disclosed going-concern language, highlighting the dependency on successful fundraising to extend its operational runway beyond the second quarter of 2027.

Recent events include an 8-K filing with material items related to equity transactions and other corporate actions, indicating active capital management. The company has engaged in multiple private placements and public offerings, including Series D and E preferred stock issuances, to secure funding for its development programs. These activities underscore the ongoing need for external capital to support the company's research and development efforts in the absence of product revenue.

Cellectar Biosciences, Inc. (CLRB) has recorded a notable addition to its shareholder base, marking the first analysis for this ticker with no prior basis for delta computation. This initial snapshot highlights a specific institutional activity that warrants attention as the company establishes its current financial profile. The primary signal is a new holder addition detected on June 28, 2026. According to the data, an investor identified by ID 466 acquired a position in the company, with the holding reported as of June 30, 2024. This transaction represents a fresh entry into the company's ownership structure. The new position consists of 228,930 shares, valued at approximately $0.57 million. This stake accounts for a weight of roughly 0.0013% of the total, indicating a relatively small but distinct allocation by the investor. The timing of the detection in mid-2026 contrasts with the reporting date of the holding, suggesting a lag in data availability or reporting cycles. Contextualizing this move, Cellectar Biosciences currently lists one officer and has no analyst coverage or index memberships. With only seven top holders identified, the addition of a new investor adds to a limited pool of significant shareholders. This change underscores the evolving interest in the company despite its current lack of broader market analyst attention.

Operating income -$5.8M.

• ▍Operating income -$5.8M

Operating income -$17.3M.

• ▍Operating income -$17.3M

Operating income -$12.4M.

• ▍Operating income -$12.4M

Operating income -$23.0M.

• ▍Operating income -$23.0M

Operating income -$51.8M.

• ▍Operating income -$51.8M

Operating income -$51.8M.

• ▍Operating income -$51.8M

Operating income -$39.0M.

• ▍Operating income -$39.0M

Operating income -$39.0M.

• ▍Operating income -$39.0M